Results 251 to 260 of about 111,871 (303)

'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer. [PDF]

Biochem Soc Trans
Buckley-Benbow L, Agnarelli A, Bellelli R.   +2 more
europepmc   +1 more source

Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. [PDF]

Nucleic Acids Res
McGehee CD, Meng XW, Wu X, Correia C, Venkatachalam A, Flatten KS, Peterson KL, Patel AG, Rossman OK, Wong C, Hurley RM, Wagner JM, Schneider PA, Dai H, Poirier GG, Hendrickson AEW, Swisher EM, Pandey A, Li H, Kaufmann SH.   +19 more
europepmc   +1 more source

Case Report: Bevacizumab combined with chemotherapy followed by PARP inhibitor maintenance therapy in <i>POLE</i>-mutated primary fallopian tube carcinoma: a case of precision treatment in a rare gynecologic malignancy. [PDF]

Front Med (Lausanne)
Cheng D, Huang X, Liu P, Liu X, He W.
europepmc   +1 more source

DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. [PDF]

Cancers (Basel)
Oda S, Kawakubo K, Kuwatani M, Tanaka S, Nakajima K, Shiratori S, Yonemura H, Nozawa S, Hirata K, Sugiura R, Sakamoto N.   +10 more
europepmc   +1 more source

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [PDF]

EJNMMI Res
Weng CC, Chiang CC, Chung YH, Ho YP, Chang YC, Hsiao IT, Mach RH.   +6 more
europepmc   +1 more source

Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor. [PDF]

ESMO Open
Kim JH, Lim MC.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tackling PARP inhibitor resistance

Trends in Cancer, 2021
Homologous recombination-deficient (HRD) tumours, including those harbouring mutations in the BRCA genes, are hypersensitive to treatment with inhibitors of poly(ADP-ribose) polymerase (PARPis). Despite high response rates, most HRD cancers ultimately develop resistance to PARPi treatment through reversion mutations or genetic/epigenetic alterations to
Fugger, Kasper, Hewitt, Graeme, West, Stephen C., Boulton, Simon J.   +3 more
openaire   +3 more sources

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources

Expanding biomarkers for PARP inhibitors

Nature Cancer, 2022
International audience ; The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures ...
Florence Coussy, Francois-Clement Bidard
openaire   +3 more sources

PARP inhibitor combination therapy

Critical Reviews in Oncology/Hematology, 2016
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.
Dréan, A, Lord, CJ, Ashworth, A
openaire   +3 more sources